By Christian Ingram Young athletes were found to be at an elevated risk for injury as they aged, engaged in sport-specialized training and when they spent a disproportionate amount of time in organized sports vs. free play time, according to
All News
By Casey Tingle Although research has shown satisfactory outcomes for total ankle arthroplasty in patients with preoperative coronal plane deformity of greater than 10°, it is still considered a relative contraindication; however, researchers recently reported the effective use of total
Scientists have discovered a way to regrow bone tissue using the protein signals produced by stem cells. This technology could help treat victims who have experienced major trauma to a limb, like soldiers wounded in combat or casualties of a
By Oriol Guell Political corruption and corporate fraud have come together in the Catalan city of Reus (Tarragona) to create an unprecedented medical crisis in Spain. For several months, a public hospital was using defective or expired surgical orthope…
By Bilioine Young Progenza, a stem cell product made by Regeneus LTD, will be the subject of a clinical trial designed to determine the safety, tolerability and preliminary efficacy of intra-articular Progenza in adults with symptomatic knee osteoarthr…
By Masoud Bidgoli Tornier NV (NASDAQ:TRNX) VP Stephan Epinette sold 62,666 shares of the company’s stock on the open market in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $25.00, for a total transaction of $1,566,650.00. Following the
First quarter net sales were $5.9 million Generated $275 thousand of cash from operations in the first quarter FITCHBURG, Mass., May 13, 2015 (GLOBE NEWSWIRE) — Arrhythmia Research Technology, Inc. (NYSE MKT:HRT) (the “Company”), through its wholly-owned subsidiary, Micron Products,
Spine Pain Management, Inc. (OTCQB:SPIN) Q1 2015 Earnings Conference Call May 13, 2015 4:20 PM ET Operator Welcome ladies and gentlemen to the Spine Pain Management 2015 First Quarter Investor Webinar Conference Call. Before we get started with our pan…
Integra LifeSciences Holdings Corporation IART, +0.55% today announced that Keith Valentine, Chief Executive Officer of SeaSpine, will join Integra to present at the 2015 UBS Global Healthcare Conference. Glenn Coleman, Integra’s Chief Financial Officer and Mr. Valentine will present at 10:30AM ET on
© 2025 MedDeviceJobs.com | Powered by Careerleaf
v.4.6.7-9-gdb70438